AIMD
Price
$0.54
Change
-$0.01 (-1.82%)
Updated
May 2 closing price
Capitalization
6.73M
XLO
Price
$0.75
Change
-$0.00 (-0.00%)
Updated
May 2 closing price
Capitalization
38.84M
4 days until earnings call
Ad is loading...

AIMD vs XLO

Header iconAIMD vs XLO Comparison
Open Charts AIMD vs XLOBanner chart's image
Ainos
Price$0.54
Change-$0.01 (-1.82%)
Volume$132.09K
Capitalization6.73M
Xilio Therapeutics
Price$0.75
Change-$0.00 (-0.00%)
Volume$58.91K
Capitalization38.84M
AIMD vs XLO Comparison Chart
Loading...
AIMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIMD vs. XLO commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIMD is a Hold and XLO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (AIMD: $0.54 vs. XLO: $0.75)
Brand notoriety: AIMD and XLO are both not notable
AIMD represents the Medical Specialties, while XLO is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIMD: 66% vs. XLO: 17%
Market capitalization -- AIMD: $6.73M vs. XLO: $38.84M
AIMD [@Medical Specialties] is valued at $6.73M. XLO’s [@Biotechnology] market capitalization is $38.84M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $299.17B to $0. The average market capitalization across the [@Medical Specialties] industry is $8.41B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIMD’s FA Score shows that 0 FA rating(s) are green whileXLO’s FA Score has 0 green FA rating(s).

  • AIMD’s FA Score: 0 green, 5 red.
  • XLO’s FA Score: 0 green, 5 red.
According to our system of comparison, both AIMD and XLO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIMD’s TA Score shows that 5 TA indicator(s) are bullish while XLO’s TA Score has 3 bullish TA indicator(s).

  • AIMD’s TA Score: 5 bullish, 6 bearish.
  • XLO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AIMD is a better buy in the short-term than XLO.

Price Growth

AIMD (@Medical Specialties) experienced а -0.92% price change this week, while XLO (@Biotechnology) price change was -9.45% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.26%. For the same industry, the average monthly price growth was -1.11%, and the average quarterly price growth was -1.23%.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

AIMD is expected to report earnings on Feb 28, 2024.

XLO is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Medical Specialties (+1.26% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XLO($38.8M) has a higher market cap than AIMD($6.73M). AIMD YTD gains are higher at: 18.421 vs. XLO (-21.445). AIMD has higher annual earnings (EBITDA): -8.75M vs. XLO (-58M). XLO has more cash in the bank: 55.3M vs. AIMD (1.89M). AIMD has less debt than XLO: AIMD (5.96M) vs XLO (8.14M). XLO has higher revenues than AIMD: XLO (6.34M) vs AIMD (122K).
AIMDXLOAIMD / XLO
Capitalization6.73M38.8M17%
EBITDA-8.75M-58M15%
Gain YTD18.421-21.445-86%
P/E RatioN/AN/A-
Revenue122K6.34M2%
Total Cash1.89M55.3M3%
Total Debt5.96M8.14M73%
FUNDAMENTALS RATINGS
AIMD: Fundamental Ratings
AIMD
OUTLOOK RATING
1..100
27
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
56
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AIMDXLO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AIMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FULC5.621.24
+28.31%
Fulcrum Therapeutics
SPG161.772.90
+1.83%
Simon Property Group
GLOB119.492.06
+1.75%
Globant SA
OMCL31.16-0.22
-0.70%
Omnicell
JRSH3.01-0.03
-0.83%
Jerash Holdings (US)

AIMD and

Correlation & Price change

A.I.dvisor tells us that AIMD and CRMD have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIMD and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIMD
1D Price
Change %
AIMD100%
-0.92%
CRMD - AIMD
28%
Poorly correlated
-2.80%
MBOT - AIMD
27%
Poorly correlated
-1.24%
POAI - AIMD
26%
Poorly correlated
-5.98%
XLO - AIMD
26%
Poorly correlated
-0.64%
CODX - AIMD
26%
Poorly correlated
+0.82%
More

XLO and

Correlation & Price change

A.I.dvisor tells us that XLO and CRMD have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XLO and CRMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XLO
1D Price
Change %
XLO100%
-0.64%
CRMD - XLO
31%
Poorly correlated
-2.80%
AXON - XLO
31%
Poorly correlated
+1.14%
VKTX - XLO
30%
Poorly correlated
+2.60%
VTGN - XLO
27%
Poorly correlated
+0.64%
AVTX - XLO
27%
Poorly correlated
N/A
More